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The best marker for the monitoring of immune
alterations in critically ill patients (sepsis, trauma,
pancreatitis, surgery, burns) so far remains decreased
HLA-DR expression on monocytes measured by flow
cytometry as it regularly provides valuable information
in terms of mortality prediction or evaluation of risk
for secondary infections. As shown by Cajander and
colleagues in a recent issue of Critical Care, some
promising tools-based molecular biology may
circumvent some drawbacks related to flow cytometry.
Herein, issues and perspectives about this alternative are
discussed.an excellent marker of monocyte functionality and anergyThe work by Cajander and colleagues provides preliminary
results in quantitation of HLA-DR by real-time polymerase
chain reaction as an alternative approach to identify pa-
tients presenting with sepsis-induced immunosuppression
[1]. Clinical observations and postmortem biopsies have
shown that many severe septic patients survive the first
critical hours of the syndrome but eventually die in a state
of immunosuppression [2]. This immune failure is illus-
trated by patients’ difficulty to fight the primary bacterial
infection, decreased resistance to secondary nosocomial
infections and reactivation of viral infections usually patho-
genic only in immunocompromised hosts. As a conse-
quence, immunostimulatory therapies are now considered
an innovative adjunctive strategy for the treatment of sepsis
[2]. However, the first critical step is to beforehand identify
patients who would actually benefit from these therapies
(that is, the most immunosuppressed) [3]. In the absence of* Correspondence: guillaume.monneret@chu-lyon.fr
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© BioMed Central Ltd.2014specific clinical signs of their immune response, it is there-
fore critical to base our judgement on biomarkers reflecting
patients’ immune status (a missing step in previous clinical
trials in the field). This rather pragmatic approach was re-
cently commented on in Critical Care for the importance
of monitoring immune functions for putative anti-program
death-1 (that is, an immunostimulatory drug) use in
patients: ‘Nobody would give insulin without glucose moni-
toring to prevent useless treatment of normoglycaemic or
hypoglycaemic patients’ [4].
The best marker for the monitoring of immune alter-
ations in critically ill patients so far remains decreased
HLA-DR expression on monocytes (mHLA-DR) measured
by flow cytometry [3]. The level of HLA-DR expression is
(that is, it correlates with decreased antigen presentation
capacity and proinflammatory cytokine release). On the
clinical side, it is the most frequently assessed marker in
various ICU conditions (sepsis, trauma, pancreatitis, sur-
gery, burns, and so forth) and provides valuable informa-
tion in terms of mortality prediction or evaluation of risk
for secondary infections [3]. That given, HLA-DR expres-
sion measurement has a couple of drawbacks. First, cell
staining should be performed within 2 hours after sampling
(can be delayed until 4 hours if blood is stored at +4°C).
This time dependency implies that flow cytometry facilities
should be available/present in every hospital. Second, as
flow cytometry is not considered a technology for emer-
gency measurements, laboratories using this technique are
usually not open 24/7. These two arguments may limit op-
portunities to conduct studies based on mHLA-DR values.
To circumvent those drawbacks, Cajander and col-
leagues presently report on measurement of HLA-DR by
quantitative reverse transcription polymerase chain reac-
tion (qRT-PCR) as a novel approach to identify im-
munosuppression in sepsis [1]. The authors established
correlations between HLA-DRA/class II transactivator
mRNA levels and the monocyte cell surface HLA-DR
protein expression measured by flow cytometry. Our
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inary results (that is, we performed correlation of six
genes coding for different molecules of CMH II complex
and mHLA-DR with regard to prediction of mortality in
sepsis [5]). Only one point that should be noted regard-
ing the present work is that reported mHLA-DR values
measured by flow cytometry are only very slightly de-
creased (that is, mean 19,000 antibodies bound per cell)
while the threshold for normal values is regularly
reported above 20,000 antibodies bound per cell [6].
Because values below 10,000 antibodies bound per cell
are regularly reported in septic patients, this correlation
still needs to be performed for such markedly decreased
values as it more appropriately refers to the clinical
decision-making values.
Surprisingly, since the pioneering works by Pachot and
colleagues [7] and Le Tulzo and colleagues [8] nothing has
been published on this aspect while more than 100 articles
have dealt with flow cytometry results. This probably
highlights the difficulty to translate this transcriptomic ap-
proach to a more routine use. Indeed, if major progresses
have been made within the last decade regarding the qRT-
PCR technique in microbiology (quality controls, auto-
mated systems, and so forth), no standardised tool for
monitoring host response biomarkers is currently avail-
able. Although the putative development of automated
systems may represent a possible perspective, for now host
response mRNA measurement remains based on home-
made protocols. Also, no data are available regarding re-
sults standardisation (interlaboratory assessment) and
analytical specifications (reproducibility, coefficient vari-
ation). In line, the question of which reference genes
should be used remains an intense matter of debate.
Another issue to minutely decipher is the relative im-
pact of each cell subpopulation expressing HLA-DR as
analyses are mostly performed on whole blood (PAX-
GENE tubes). Therefore, the evaluation of HLA-DR by
qRT-PCR often combines expressions from monocytes,
dendritic cells, B lymphocytes and activated T cells
whereas flow cytometry specifically measures the mono-
cytic level. In contrast, a standardised flow cytometry
protocol for mHLA-DR measurement has been estab-
lished so as to obtain reproducible results between cen-
tres. Pre-analytical requirements were published in 2002
[9]. Subsequently, an international group of experts su-
pervised by the pioneering group from Berlin then de-
fined a consensually accepted standardised protocol in
2005 [6]. Recently, we assessed the robustness of this
protocol on fresh whole blood between two centres
(Lyon and Grenoble, 100 km distance between centres)
[10]. Blood samples were separated into two aliquots
stored at +4°C and then stained and analysed at the
same time in two different laboratories on flow cyt-
ometers from different companies (Beckman-Coulter,Hialeah, FL, USA and Becton-Dickinson, San Jose, CA,
USA). We observed an excellent correlation between
mHLA-DR results [10]. Consequently, mHLA-DR by
flow cytometry is ready for multicentric studies.
We therefore come back to our title question: shall we
stop following the flow for measuring mHLA-DR? The
response is not yet, but we obviously should keep an eye
on possible improvements in mHLA-DR measurements
by qRT-PCR as this technology is in continuous devel-
opment and could offer standardised and automated
protocols.
Abbreviations
HLA-DR: Human leukocyte antigen DR; mHLA-DR: HLA-DR expression on




1. Cajander S, Bäckman A, Tina E, Strålin K, Söderquist B, Källman J: Preliminary
results in quantitation of HLA-DRA by real-time PCR: a promising ap-
proach to identify immunosuppression in sepsis. Crit Care 2013, 17:R223.
2. Hotchkiss RS, Monneret G, Payen D: Immunosuppression in sepsis: a novel
understanding of the disorder and a new therapeutic approach.
Lancet Infect Dis 2013, 13:260–268.
3. Venet F, Lukaszewicz AC, Payen D, Hotchkiss R, Monneret G: Monitoring
the immune response in sepsis: a rational approach to administration of
immunoadjuvant therapies. Curr Opin Immunol 2013, 25:477–483.
4. Volk HD, Reinke P: To be, or not to be immunocompetent. Crit Care 2013,
17:185.
5. Cazalis M, Friggeri A, Cavé L, Demaret J, Barbalat V, Cerrato E, Lepape A,
Pachot A, Monneret G, Venet F: Decreased HLA-DR antigen-associated in-
variant chain (CD74) mRNA expression predicts mortality after septic
shock. Crit Care 2013, 17:R287.
6. Docke WD, Hoflich C, Davis KA, Rottgers K, Meisel C, Kiefer P, Weber SU,
Hedwig-Geissing M, Kreuzfelder E, Tschentscher P, Nebe T, Engel A, Mon-
neret G, Spittler A, Schmolke K, Reinke P, Volk HD, Kunz D: Monitoring tem-
porary immunodepression by flow cytometric measurement of
monocytic HLA-DR expression: a multicenter standardized study. Clin
Chem 2005, 51:2341–2347.
7. Pachot A, Monneret G, Brion A, Venet F, Bohe J, Bienvenu J, Mougin B,
Lepape A: Messenger RNA expression of major histocompatibility
complex class II genes in whole blood from septic shock patients. Crit
Care Med 2005, 33:31–38. discussion 236–237.
8. Le Tulzo Y, Pangault C, Amiot L, Guilloux V, Tribut O, Arvieux C, Camus C,
Fauchet R, Thomas R, Drenou B: Monocyte human leukocyte antigen-DR
transcriptional downregulation by cortisol during septic shock.
Am J Respir Crit Care Med 2004, 169:1144–1151.
9. Monneret G, Elmenkouri N, Bohe J, Debard AL, Gutowski MC, Bienvenu J,
Lepape A: Analytical requirements for measuring monocytic human
lymphocyte antigen DR by flow cytometry: application to the
monitoring of patients with septic shock. Clin Chem 2002, 48:1589–1592.
10. Demaret J, Walencik A, Jacob MC, Timsit JF, Venet F, Lepape A, Monneret G:
Inter-laboratory assessment of flow cytometric monocyte HLA-DR ex-
pression in clinical samples. Cytometry B Clin Cytom 2013, 84:59–62.
Cite this article as: Monneret and Venet: Monocyte HLA-DR in sepsis: shall
we stop following the flow?. Critical Care
06 Jan 2014
10.1186/cc13179
2014, 18:102
